Background {#Sec1}
==========

Diabetes mellitus (DM) and hyperglycemia negatively affect the outcome and pathophysiology of acute ischemic stroke. The associations between DM and early neurological deterioration (END) \[[@CR1], [@CR2]\], more comorbidities \[[@CR3]\], severe handicap and disability \[[@CR4], [@CR5]\], and increased mortality \[[@CR3]\], have been repeatedly reported in both case-control \[[@CR6]\] and cohort studies \[[@CR7]\]. When the effects of hyperglycemia are included, these patients also present with more severe lesion size \[[@CR8]\], more symptomatic intracranial hemorrhages \[[@CR9], [@CR10]\], edema \[[@CR11]\], and mortality \[[@CR12]\]. Although END is more frequently encountered in diabetic patients, the specific mechanisms underlying how DM promotes END are among the least clear. In clinical practice, being able to anticipate END would allow for more timely intervention; thus, gaining further insight into the mechanisms of END specific to patients with DM would improve the ability to identify and intervene in END in a population seemingly more susceptible to it. One possible mechanism linking DM with adverse outcomes of stroke involves fibrinogen, a prothrombotic protein, and acute phase reactant that is consistently elevated in patients with diabetes \[[@CR13], [@CR14]\]. In fact, a large body of evidence identifies fibrinogen as a mediator in the development of coronary artery thrombi and future cardiac events \[[@CR15], [@CR16]\]. However, the association of hyperfibrinogenemia and END in acute ischemic stroke has not yet been demonstrated. In this study, we evaluated whether elevated fibrinogen levels in patients with diabetes and acute ischemic stroke are associated with END in a large, single-center population.

Methods {#Sec2}
=======

Study population {#Sec3}
----------------

We performed a retrospective study that was approved by the Institutional Review Board, and performed in accordance with the ethical standards of the 1964 Declaration of Helsinki and its later amendments, incorporating consecutive patients enrolled in a hospital stroke database. From this database, we reviewed consecutive patients from Jan. 2000 to Dec. 2015. Among them, we included 3814 patients with acute ischemic stroke within 72 h of onset, and with available National Institutes of Health Stroke Scale (NIHSS) data.

Data acquisition {#Sec4}
----------------

For this study, the diagnosis of DM was defined as either a prior diagnosis of diabetes, or glycated hemoglobin (HbA1c) levels \>6.1% at admission, according to a previous study which showed that prediabetic levels of hba1c \>6.1% were associated with increased stroke recurrence \[[@CR17]\]. Lab data concerning the hemostatic profiles such as fibrinogen, fibrin degradation products (FDP), D-dimer, and classic stroke risk factors were obtained on the day of admission, before initiation of intravenous tissue plasminogen activators for those who were applicable. Acute inflammatory markers, erythrocyte sedimentation rate (ESR), and standard C-reactive protein (CRP) levels were included in the analysis, to compare with fibrinogen. Components of metabolic syndrome were also analyzed. Lab data routinely taken to evaluate diabetic status, such as fasting glucose levels, urine glucose, urine protein, and HbA1c levels were also included in the analysis. Trial of Org 10,172 in Acute Stroke Treatment (TOAST) classification, and NIHSS scores on admission and at discharge were also collected from the database.

Propensity score matching and statistical analysis {#Sec5}
--------------------------------------------------

END was defined as a NIHSS score increase of 2 or more within 7 days after admission. A number of studies have, for the definition of END, used an increase of ≥2 points in the total NIHSS score within 7 days \[[@CR18]\], as modified from a previous study. We have incorporated such sensitive criteria to define END for such subtle changes call for action in clinical practice. Because END in patients with acute ischemic stroke can be influenced by a greater initial NIHSS and TOAST classification, we used propensity score matching to adjust for well-known confounding factors. First, among the 3814 patients with acute stroke, we performed univariate and multivariate analyses to document the effects of fibrinogen and other predictive factors of END. Multivariate analysis was performed, adjusting for age, sex, presence of hypertension, diabetes mellitus, initial NIHSS score, and TOAST classification. The *p* value for the diabetes status x fibrinogen level interaction was also calculated in the logistic regression model. For subgroup analysis, the patients were divided into DM (*n* = 1360) and non-DM (*n* = 2454) populations. In each subgroup, a 1:2 propensity score matching of END patients and non-END patients was performed, adjusting for age, sex, initial NIHSS score, and TOAST classification (Additional file [1](#MOESM1){ref-type="media"}: Figure S1A-B). Differences between the two groups were analyzed before and after propensity score matching, using a χ^2^ test for categorical variables and Student's *t*-test for continuous variables. Multiple logistic regression analysis was performed, adjusting for baseline clinical variables known to be associated with END such as age, sex, hypertension, initial NIHSS, and TOAST classification, as well as with potentially significant factors determined in the univariate analysis (*p* \< 0.005), to verify the significance of fibrinogen levels on END. All statistical analyses were performed using IBM SPSS Statistics 20 software (Chicago, IL).

Results {#Sec6}
=======

Among 3814 patients with acute stroke, 661 cases (17.3%) experienced early neurological deterioration. Patients in the END group were significantly older (65.3 ± 12.6 vs. 63.5 ± 13.5, *p* = 0.001), and more frequently had a history of DM (39.6% vs. 34.8%, *p* = 0.019), a history of hypertension (70.0% vs. 65.8%, *p* = 0.039), a higher initial NIHSS (8.2 ± 6.7 vs. 5.6 ± 6.3, *p* \< 0.001), higher fasting glucose (151 ± 66 vs. 144 ± 63 mg/dL, *p* = 0.005), higher urine protein positivity (22.7% vs. 14.6%, *p* \< 0.001), and higher fibrinogen levels (367 ± 156 vs. 347 ± 122 mg/dL, *p* = 0.002) (Table [1](#Tab1){ref-type="table"}). In the multiple regression analysis of the total population, higher fibrinogen levels were not significantly associated with END after adjusting for confounders (*p* = 0.195) (Table [2](#Tab2){ref-type="table"}). The interaction between diabetes status and fibrinogen levels regarding END was not statistically significant in the entire cohort (*p* = 0.101).Table 1Comparison of baseline data in patients with acute ischemic stroke admitted within 72 hEND (*n* = 661)Non-END (*n* = 3153)PAge65.3 ± 12.663.5 ± 13.50.001Male sex409 (61.9%)2017 (64.0%)0.309Hypertension462 (70.0%)2052 (65.8%)0.039Diabetes mellitus262 (39.6%)1098 (34.8%)0.019Initial NIHSS8.2 ± 6.75.6 ± 6.3\<0.001Discharge NIHSS10.5 ± 10.33.2 ± 5.4\<0.001TOAST\<0.001 Cardioembolism160 (24.2%)718 (22.8%) Atherosclerosis201 (30.4%)818 (25.9%) Small artery disease159 (24.1%)614 (19.5%) Others141 (21.3%)1003 (31.8%)Fasting glucose (mg/dL)151 ± 66144 ± 630.005Glycated hemoglobin (%)6.65 ± 1.576.46 ± 1.360.051Urine protein positivity100/441 (22.7%)276/1896 (14.6%)\<0.001Fibrinogen (mg/dL)367 ± 156347 ± 1220.002ESR (mm)18.15 ± 17.0917.57 ± 17.010.439CRP (mg/dL)0.81 ± 2.000.73 ± 2.330.459BMI23.8 ± 3.224.0 ± 3.40.163Metabolic syndrome288 (43.6%)1295 (41.1%)0.236Lipid panel T.chol (mg/dL)179.54 ± 42.07179.15 ± 51.460.857 LDL (mg/dL)107.42 ± 37.48105.68 ± 35.450.262 HDL (mg/dL)45.65 ± 12.8745.94 ± 13.400.616 TG (mg/dL)139.77 ± 122.26142.83 ± 117.810.552*END* early neurological deterioration, *NIHSS* National Institutes of Health Stroke Scale, *TOAST* trial of Org 10,172 in acute stroke treatment, *ESR* erythrocyte sedimentation rate, *CRP* c-reactive protein, *BMI* body mass index, *T.chol* total cholesterol, *LDL* low density lipoprotein, *HDL* high density lipoprotein, *TG* triglyceride Table 2A logistic regression model including potential factors associated with early neurologic deterioration in patients with acute ischemic stroke admitted within 72 hOdds ratio (95% confidence interval)PAge1.00 (1.00--1.01)0.605Male sex0.94 (0.78--1.14)0.551Hypertension1.14 (0.93--1.40)0.194Diabetes mellitus1.11 (0.92--1.33)0.268Initial NIHSS1.07 (1.05--1.08)\<0.001TOAST\<0.001 CardioembolismReference Atherosclerosis1.38 (1.07--1.78)0.013 Small artery disease1.97 (1.48--2.63)\<0.001 Others0.94 (0.71--1.24)0.652Fibrinogen (mg/dL)0.195 0--300 mg/dLReference 300--600 mg/dL1.20 (0.97--1.49)0.091  \> 600 mg/dL1.36 (0.78--2.37)0.195*NIHSS* National Institutes of Health Stroke Scale, *TOAST* trial of Org 10,172 in acute stroke treatment

There were 1360 diabetic and 2454 non-diabetic patients. In the DM population (END = 262, non-END = 1098), a diagnosis of hypertension (81.6% vs. 74.6%, *p* = 0.017), initial NIHSS (10.4 ± 10.6 vs. 3.6 ± 5.7, *p* \< 0.001), urine protein positivity (35.1% vs. 21.2%, *p* \< 0.001), and fibrinogen levels (392.9 ± 204.2 mg/dL, *p* = 0.012) were significantly higher in the END population versus the non-END population (Table [3](#Tab3){ref-type="table"}). Propensity score matching was performed for age, sex, initial NIHSS, and TOAST classification, with a relative multivariate imbalance measure L1 of 0.621 before matching, and 0.609 after matching. No covariate exhibited a large imbalance. After matching, proteinuria (34.7% vs. 23.4%, *p* = 0.007, and hyperfibrinogenemia (392.8 ± 204.6 vs. 361 ± 123.1 mg/dL, *p* = 0.009) were still significantly associated with END (Table [3](#Tab3){ref-type="table"}). In the propensity score-matched population, further logistic regression analysis adjusting for age, sex, hypertension, TOAST classification, and positive proteinuria was done, and fibrinogen was significantly associated with END in the DM population (fibrinogen \<300 mg/dL as reference; fibrinogen levels 300 \~ 599 mg/dL, odds ratio: 1.618, 95% confidence interval: 1.037--2.525, *p* = 0.034, fibrinogen levels ≥600 mg/dL, 2.575, 1.018--6.514, *p* = 0.046) (Table [4](#Tab4){ref-type="table"}).Table 3Comparison before and after propensity score matching^a^ in patients with diabetes and acute ischemic stroke admitted within 72 hBefore matchingAfter matchingEND (*n* = 262)Non-END (*n* = 1098)PEND (*n* = 261)Non-END (*n* = 522)PAge65.3 ± 11.865.1 ± 11.70.77165.3 ± 11.864.8 ± 11.80.593Male sex160 (61.1%)700 (63.8%)0.418159 (60.9%)315 (60.3%)0.877Hypertension213 (81.6%)812(74.6%)0.017213 (81.6%)431 (82.6%)0.741Initial NIHSS8.0 ± 6.65.7 ± 6.4\<0.0017.9 ± 6.67.6 ± 6.80.562Discharge NIHSS10.4 ± 10.63.6 ± 5.7\<0.00110.4 ± 10.54.8 ± 6.5\<0.001TOAST0.16776 (23.4%)0.169 Cardioembolism52 (19.8%)221 (20.1%)52 (19.9%)111 (21.3%) Atherosclerosis88 (33.6%)328 (29.8%)88 (33.7%)163 (31.2%) Small artery disease64 (24.4%)235 (21.4%)64 (24.5%)102 (19.5%) Others58 (22.1%)314 (28.6%)57 (21.8%)146 (28.0%)Fasting glucose (mg/dL)190.9 ± 84.1184.0 ± 85.50.238190.7 ± 84.2189.5 ± 87.80.852Glycated hemoglobin (%)7.5 ± 1.77.3 ± 1.50.1197.5 ± 1.77.4 ± 1.60.392Urine protein positivity59 (35.1%)143 (21.2%)\<0.00158 (34.7%)76 (23.4%)0.007Fibrinogen (mg/dL)392.9 ± 204.2359.0 ± 119.10.012392.8 ± 204.6361.1 ± 123.10.009ESR (mm)22.0 ± 20.521.2 ± 20.10.54722.0 ± 20.521.3 ± 18.90.643CRP (mg/dL)0.9 ± 2.30.9 ± 2.80.9310.9 ± 2.31.1 ± 3.20.528BMI24.2 ± 3.324.5 ± 3.20.317Metabolic syndrome149 (56.9%)609 (55.5%)0.681149 (57.1%)305 (58.4%)0.720Lipid panel T.chol (mg/dL)179.6 ± 43.2181.7 ± 69.00.629179.3 ± 43.0182.2 ± 47.40.396 LDL (mg/dL)106.3 ± 37.7106.1 ± 37.40.919106.0 ± 37.4107.5 ± 38.10.604 HDL (mg/dL)43.7 ± 11.743.9 ± 15.00.82543.7 ± 11.744.0 ± 12.10.775 TG (mg/dL)158.6 ± 113.5163.4 ± 133.40.600158.7 ± 113.7165.6 ± 153.30.521*END* early neurological deterioration, *NIHSS* National Institutes of Health Stroke Scale, *TOAST* trial of Org 10,172 in acute stroke treatment, *ESR* erythrocyte sedimentation rate, *CRP* c-reactive protein, *BMI* body mass index, *T.chol* total cholesterol, *LDL* low density lipoprotein, *HDL* high density lipoprotein, *TG* triglyceride^a^ Age, sex, initial NIHSS and TOAST were adjusted Table 4A logistic regression model for END after propensity score matching^a^ in patients with diabetes mellitus admitted within 72 h of acute ischemic strokeOdds ratio (95% confidence interval)PAge1.01 (0.99--1.03)0.397Male sex1.22 (0.80--1.87)0.352Hypertension1.01 (0.584--1.74)0.982Initial NIHSS1.01 (0.98--1.05)0.434TOAST0.098 CardioembolismReference Atherosclerosis1.24 (0.71--2.16)0.445 Small artery disease2.01 (1.00--4.02)0.049 Others0.95 (0.51--1.75)0.858Positive urine proteins1.40 (0.90--2.17)0.140Fibrinogen per 300 mg/dl0.044 0--300 mg/dLReference 300--600 mg/dL1.62 (1.04--2.53)0.034  \> 600 mg/dL2.60 (1.02--6.51)0.046*END* early neurological deterioration, *NIHSS* National Institutes of Health Stroke Scale, *TOAST* trial of Org 10,172 in acute stroke treatment^a^ Age, sex, initial NIHSS and TOAST were adjusted

In the non-DM population (END = 399, Non-END = 2055), age (65.3 ± 13.2 vs. 62.7 ± 14.3, *p* \< 0.001), initial NIHSS (8.4 ± 6.8 vs. 5.6 ± 6.3, *p* \< 0.001), and fasting glucose levels (125.6 ± 30.9 vs. 122.1 ± 29.7 mg/dL, *p* = 0.036) were significantly higher in the END group, as were differences in TOAST classification (*p* \< 0.001) (Additional file [2](#MOESM2){ref-type="media"}: Table S1). Propensity score matching was performed for age, sex, initial NIHSS, and TOAST classification, with a relative multivariate imbalance measure L1 of 0.581 before matching, and 0.525 after matching. No covariate exhibited a large imbalance. After matching, TOAST classification (*p* = 0.003), elevated total cholesterol (179.5 ± 41.3 vs. 173.6 ± 38.4 mg/dL, *p* = 0.015), and elevated low density lipoprotein (108.2 ± 37.4 vs. 102.8 ± 34.3 mg/dL, *p* = 0.015) were significantly associated with END (Additional file [2](#MOESM2){ref-type="media"}: Table S1). In further regression analysis in the matched population, including age, male sex, presence of hypertension, initial NIHSS, TOAST classification, and total cholesterol levels as covariables, fibrinogen did not prove to be associated with END (*p* = 0.393) (Additional file [2](#MOESM2){ref-type="media"}: Table S2).

Discussion {#Sec7}
==========

The results of this study suggest that hyperfibrinogenemia in patients with acute stroke and DM is associated with END, using both propensity score matching and multiple logistic regression analysis. Whereas the influence of hyperfibrinogenemia on END was consistently seen in the DM subgroup, it disappeared in the non-DM subgroup.

Hyperfibrinogenemia itself may directly induce a higher frequency of END in diabetic individuals through activation of the coagulation cascade. Fibrinogen forms fibrin clots as part of the final common stages of both the extrinsic and intrinsic pathways of the coagulation cascade \[[@CR19]\]. Atherogenesis and the growth of atheromatous lesions are also initiated in part by fibrin deposition \[[@CR20], [@CR21]\]. Fibrinogen also facilitates platelet aggregation by binding to the glycoprotein IIb/IIIa receptor, increasing its reactivity \[[@CR22]\].

Hyperfibrinogenemia may also indirectly reflect a prothrombotic condition induced by hyperinsulinemia and prolonged glycation. Levels of fibrinogen in diabetic patients correlate with insulin resistance and metabolic syndrome \[[@CR13]\]. Prolonged glycation also induces a prothrombotic condition. Studies on fibrin clot structure under diabetic conditions have shown fibrinogen to be glycated in vivo \[[@CR23]\], causing a change in the fibrin clot structure that reduces permeability \[[@CR24]\], decreases fibrinolysis \[[@CR25]\], and decreases α-chain crosslinking \[[@CR26]\]. Thus, the effects of insulin resistance and prolonged glycation increase the risk of thrombosis, which underpins the development of vascular disease \[[@CR27]\]. These studies lead us to assume that fibrinogen levels may represent a marker of platelet aggregation or progression to a prothrombotic phenotype in patients with diabetes \[[@CR27]\].

This is the first study to link diabetic hyperfibrinogenemia to a higher frequency of END after ischemic stroke. Epidemiological studies have established that elevated fibrinogen levels are strongly and independently correlated with the risks of coronary arterial disease (CAD), stroke, and peripheral arterial disease \[[@CR16], [@CR28]--[@CR31]\]. In stroke, carotid artery stenosis is significantly associated with elevated fibrinogen levels \[[@CR32]\], and placebo data analysis in the Stroke Treatment with Ancrod Trial (STAT) and European Stroke Treatment with Ancrod Trial (ESTAT) has shown that plasma fibrinogen levels at stroke onset are independently associated with a poor functional outcome \[[@CR33]\]. However, it has not been reported that hyperfibrinogenemia in patients with diabetes is associated with END in the acute stroke period.

It is conceivable that stronger antiplatelet treatments might be needed for patients with diabetes and hyperfibrinogenemia following acute ischemic stroke. Of note, elevated fibrinogen levels in our group of patients with diabetes may be linked to antiplatelet resistance, which may in turn result in END. Previous large scale trials, such as the Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes (JPAD) trial \[[@CR34]\], and the Prevention of Progression of Arterial Disease and Diabetes (POPAPAD) trial \[[@CR35]\], have shown low efficacy of aspirin monotherapy for prevention of cardiovascular events in patients with diabetes. In addition, recent data show that responses to clopidogrel in patients with diabetes are suboptimal \[[@CR36]\]. Such data suggest that diabetes is associated with considerable resistance to aspirin and clopidogrel therapy, and such insufficient antiplatelet responses could be an underlying causal factor for the frequent END observed in this population. In accordance with the elevated fibrinogen levels in our data, a recent study evaluating platelet aggregation characteristics in acute coronary syndrome found antiplatelet drug resistance to be significantly associated with metabolic syndrome, and fibrinogen levels and high sensitivity-CRP were higher in this population \[[@CR37]\]. Serum fibrinogen levels appeared to be strongly associated with drug resistance \[[@CR37]\]. In this case, elevated fibrinogen levels may call for more radical choices for antiplatelet therapy in such a population.

Apart from the antiplatelet issue, the idea that reduced fibrin, which is formed by fibrinogen in blood, may reduce blood viscosity, improve blood flow, and help remove the blood clot blocking the artery and re-establish blood flow has inspired clinical trials testing the therapeutic effects of the fibrin-depleting agents ancrod and defibrase \[[@CR38]\]. In eight trials involving 5701 patients, fibrin-depleting agents marginally reduced the proportion of patients who were dead or disabled at the end of follow-up, and there were fewer stroke recurrences in the treatment group than in the control group. However, symptomatic intracranial hemorrhage was about twice as common in the treatment group compared with the control group \[[@CR38]\]. The use of fibrin-depleting agents to reduce blood viscosity in patients with DM and elevated fibrinogen at risk for END holds similar problems. Plasma fibrinogen levels are associated with silent cerebrovascular lesions \[[@CR39]\], and although this relationship may be evidence that increased viscosity by fibrinogen is a risk factor for stroke, deep white matter hyperintensities, on the other hand, are a known risk factor for intracerebral hemorrhage \[[@CR40]\]. Accordingly, the use of fibrin-depleting agents in patients with DM may confer a higher risk of hemorrhagic complications. Thus, while the selective use of fibrin-depleting agents in patients with DM and END may be considered, further clinical studies to address the risks are needed prior to making such treatment a recommendation.

We acknowledge that our study has limitations. First, due to the retrospective nature of the study, there may be selection bias. We tried to minimize this issue by maximizing the number of patients included in the study and including adequate propensity score matching. Second, our somewhat long temporal definition of END (\<7 days) incorporates a range of heterogeneous underlying mechanisms, and different definitions are used in other reports. Due to the retrospective nature and large number of enrolled patients in the study, the heterogeneity of END could not be addressed in this study. Third, because of the focus on lab data in this study, medication factors and imaging variables such as intracranial occlusion, stenosis, or diffusion weighted image volume were not included for analysis. However, variables that may have similar implications such as TOAST classification, and NIHSS scores were included, and the large patient numbers included may supplement such limitations. We hope to address these issues in later prospective studies.

Conclusion {#Sec8}
==========

In conclusion, hyperfibrinogenemia at admission in patients with acute ischemic stroke and DM is independently associated with END. This finding suggests that an elevated fibrinogen level is a marker of a prothrombotic or antiplatelet-resistant condition related to DM that could affect the patient's prognosis. On the other hand, these results also reveal a category of patients wherein fibrin-depleting therapy could be significantly more effective.
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